Aptimmune Biologics Культура компании

Dr. M. Scot Roberts, Ph.D. has been the Chief Scientific Officer of Altimmune, Inc. (formerly Vaxin Inc.) since December 3, 2012. Dr. Roberts has almost 20 years of senior technical leadership experience, as Chief Scientific Officer at ImQuest BioSciences, Inc. where he was responsible for managing scientific operations as well as business development opportunities for the company. Prior to ImQuest, Dr. Roberts held key positions with Wellstat Biologics Corporation. Dr. Roberts has significant experience in viral research, assay development, upstream process development, animal pharmacology and drug development. Dr. Roberts completed a post-doCTOral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and has numerous patents, pending patents and publications in peer-reviewed journals. Dr. Roberts received his PhD from Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences; and a Master of Science Degree from the Chemistry Department of Illinois State University.

Dr. Sybil Tasker, M.D., M.P.H., FACP, FIDSA has been Chief Medical Officer at Altimmune, Inc. since May 16, 2017. Dr. Tasker served as Senior Vice President of Clinical Research and Development at Altimmune, Inc. since April 5, 2016 until May 16, 2017. Dr. Tasker was a Senior Director of Clinical Development and led the GEN-003 therapeutic vaccine program at Genocea Biosceiences Previously a career military officer, Dr. Tasker held senior leadership roles involving pandemic influenza and biodefense planning within the Department of Defense, in addition to patient care and clinical research activities. Following that, she guided infectious disease therapeutic area clinical development strategy at two leading global CROs, involving a wide variety of sponsors and indications, including two successful BARDA proposals for influenza vaccines and multiple pivotal phase 3 programs for antimicrobials that are on the market. Dr. Tasker received an A.B. in biochemistry from Princeton University, a Master of Public Health degree from Johns Hopkins University and an M.D. from Columbia University.

Ms. Elizabeth Adkins Czerepak has been the Chief Financial Officer of Altimmune, Inc. (formerly Vaxin, Inc.) since April 2015, Corporate Secretary since May 4, 2017 and has been its Executive Vice President of Corporate Development since January 2017. Ms. Czerepak served as the Chief Financial Officer and Chief Business Officer of Isarna Holding GmbH from April 2014 to 2015. Ms. Czerepak was the General Partner of the funds comprising the Bear Stearns Health Innoventures Group, since April 2001. She served as the Chief Financial Officer at Cancer Genetics, Inc. from January 24, 2011 to March 31, 2014 and also served as its Principal Accounting Officer until March 2014. Ms. Czerepak Co-founded BIOptima Advisors LLC in May 2009. She was a Managing Partner at Bear Stearns Health Innoventures Management, L.L.C. and Bear Stearns Health Innoventures, L.P. She also served as Managing Director and NASD Registered Representative at JP Morgan and Bear Stearns & Co. She served as an Executive Officer of Bear Stearns Asset Management Inc. She served as Vice President of Business Development at BASF PharmaChemikalien GmbH & Co. KG. She served at JPMorgan Chase & Co. She served as the Vice President of Business Development and a Member of the Executive Board at BASF Pharma and Knoll Pharmaceutical Co., participating in the direction of all operational activities. Prior to BASF, she spent nine years at Hoffmann-La Roche Inc. in senior positions responsible for licensing, acquisitions, financial analysis and strategic planning. She served as a Liaison for Roche in managing strategic deal flow from its ???window on technology??? investments in the health care-focused venture capital funds of HealthCare Ventures, CW Group, Oxford Bioscience Partners, Advent, HealthCare Ventures and others. She began her pharmaceutical career at Merck & Co., Inc., where she was a key member of the team that developed the first comprehensive, simulation-based model for predicting research and development productivity. She serves as a Director of Advancis Pharmaceutical Corp., Agensys, Inc. and Served as Director of AGY Therapeutics, Inc since 2002 until 2006. She served as a Director of MiddleBrook Pharmaceuticals, Inc. from July 2003 to August 18, 2005, Affymax, Inc. from 2004 to June 13, 2007 and PharmAthene, Inc., from August 3, 2007 to July 16, 2008. She served as a Director of Raven Biotechnologies, Inc., Radius Health, Inc. and Tolerx, Inc. Ms. Czerepak received a B.A., magna cum laude, from Marshall University and an M.B.A. in Finance from Rutgers University.